Jiantao Mo

Xi'an Jiaotong University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Qingyong Ma

First Affiliated Hospital of Xi'an Jiaotong University

Zheng Wang

First Affiliated Hospital of Xi'an Jiaotong University

Qiao‐Xin Li

Florey Institute of Neuroscience and Mental Health

Cancan Zhou

First Affiliated Hospital of Xi'an Jiaotong University

Jingjing Huang

Sun Yat-sen University

Zheng Wu

First Affiliated Hospital of Xi'an Jiaotong University

Le Lü

Alibaba Group (United States)

Weikun Qian

First Affiliated Hospital of Xi'an Jiaotong University

Mengyuan Gong

First Affiliated Hospital of Xi'an Jiaotong University

Qiqi Wang

First Affiliated Hospital of Xi'an Jiaotong University

Cooperative Institutions

First Affiliated Hospital of Xi'an Jiaotong University

Xi'an Jiaotong University

Second Affiliated Hospital of Xi'an Jiaotong University

Shanghai Jiao Tong University

Shanghai East Hospital

Chinese Academy of Sciences

Sun Yat-sen University

Chinese Academy of Medical Sciences & Peking Union Medical College

Tongji University

Huazhong University of Science and Technology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Comprehensive bioinformatics analysis reveals the prognostic value, predictive value, and immunological roles of ANLN in human cancers

Frontiers in Genetics (2022)

Zhiwei Cui Jiantao Mo Ping Song Lijun Wang Rongli Wang

Anillin (ANLN) is a unique scaffolding, actin-binding protein, which is essential for the integrity and ingression of the cleavage furrow. It is mainly involved in the cytokinesis process, while its role in various tumors has not been fully addressed and remains largely elusive. To provide a thorough perspective of ANLN's roles among diverse malignancies, we conducted a comprehensive, pan-cancer analysis about ANLN, including but not limited to gene expression levels, prognostic value, biological functions, interacting proteins, immune-related analysis, and predictive value. As a result, when compared to normal tissues, ANLN expression is elevated in most cancers, and its expression also differs in different immune subtypes and molecular subtypes in diverse cancers. In addition, in 17 types of cancer, ANLN expression is increased in early tumor stages, and higher ANLN expression predicts worse survival outcomes in more than ten cancers. Furthermore, ANLN shows close correlations with the infiltration levels of most immune cells, and enrichment analysis using ANLN co-expressed genes reveals that ANLN plays essential roles in cell cycle, mitosis, cellular senescence, and p53 signaling pathways. In the final, ANLN exhibits high accuracy in predicting many cancers, and subsequent multivariate analysis suggests ANLN could be an independent prognostic factor in specific cancer types. Taken together, ANLN is proved to be a novel and promising biomarker for its excellent predictive utility, promising prognostic value, and potential immunological roles in pan-cancer. Targeting ANLN might be an attractive approach to tumor treatment.

10.3389/fgene.2022.1000339

Cite

Citations (4)

The Study of Exosomes-Encapsulated mPEG-PLGA Polymer Drug-Loaded Particles for Targeted Therapy of Liver Cancer

Journal of Oncology (2022)

Jiantao Mo Xuanbo Da Qiao‐Xin Li Jingjing Huang Le Lü

The emergence of targeted drugs brings hope to patients with advanced liver cancer. However, due to the complex and diverse environment in the human body, the overall response rate of targeted drugs is not high. Therefore, how to efficiently deliver targeted drugs to tumor sites is a major challenge for current research. The project intends to construct mPEG-PLGA nanoparticles loaded with Sora and encapsulate them with exosomes for targeted therapy of hepatocellular carcinoma. mPEG-PLGA drug-loaded nanoparticles were prepared by the dialysis method and characterized by TEM and DLS. The obtained nanoparticles were incubated with the exosomes of liver cancer cells, and the exosomes-encapsulated drug-loaded nanoparticles (Exo-Sora-NPs) were obtained under pulsed ultrasound conditions, and they were characterized by Western blot, transmission electron microscopy (TEM), and dynamic light scattering (DLS). The toxic effect of Exo-Sora-NPs on liver cancer cells was detected by the CCK-8 experiment. The uptake efficiency of nanoparticles by liver cancer cells was detected by a confocal microscope. The accumulation and infiltration depth of nanomedicine in liver cancer tissues were observed by confocal microscope on frozen sections of liver cancer tissue after the H22 liver cancer subcutaneous tumor transplantation model was constructed. The tumor size, body weight, pathology, and serology analysis of mice were measured after administration. The mPEG-PLGA polymer drug-loaded particles encapsulated by exosomes have high targeting ability and biosafety. To a certain extent, they can target the drug to the tumor site with a smaller systemic response and have a highly effective killing effect on the tumor. Nanodrug-loaded particles encapsulated by exosomes have great potential as drug carriers.

PLGA

Liver Cancer

Targeted drug delivery

10.1155/2022/4234116

Cite

Citations (8)

NEAT1 Promotes the Perineural Invasion of Pancreatic Cancer via the E2F1/GDNF Axis

Cancer Letters (2025)

Jingtao Gu Qiqi Wang Jiantao Mo Tao Qin Weikun Qian

Perineural invasion

10.1016/j.canlet.2025.217497

Cite

Citations (0)

Pharmacological inhibition of SREBP1 suppresses pancreatic cancer growth via inducing GPX4-mediated ferroptosis

Cellular Signalling (2024)

Ruiqi Cao Zhengyuan Feng Jiantao Mo Jiaoxing Wu Jie Li

10.1016/j.cellsig.2024.111381

Cite

Citations (2)

Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets

BMC Cancer (2024)

Xuanbo Da Bangping Cao Jiantao Mo Yukai Xiang Hai Hu

Abstract Background Traditional nanodrug delivery systems have some limitations, such as eliciting immune responses and inaccuracy in targeting tumor microenvironments. Materials and methods Targeted drugs (Sorafenib, Sora) nanometers (hollow mesoporous silicon, HMSN) were designed, and then coated with platelet membranes to form aPD-1-PLTM-HMSNs@Sora to enhance the precision of drug delivery systems to the tumor microenvironment, so that more effective immunotherapy was achieved. Results These biomimetic nanoparticles were validated to have the same abilities as platelet membranes (PLTM), including evading the immune system. The successful coating of HMSNs@Sora with PLTM was corroborated by transmission electron microscopy (TEM), western blot and confocal laser microscopy. The affinity of aPD-1-PLTM-HMSNs@Sora to tumor cells was stronger than that of HMSNs@Sora. After drug-loaded particles were intravenously injected into hepatocellular carcinoma model mice, they were demonstrated to not only directly activate toxic T cells, but also increase the triggering release of Sora. The combination of targeted therapy and immunotherapy was found to be of gratifying antineoplastic function on inhibiting primary tumor growth. Conclusions The aPD-1-PLTM-HMSNs@Sora nanocarriers that co-delivery of aPD-1 and Sorafenib integrates unique biomimetic properties and excellent targeting performance, and provides a neoteric idea for drug delivery of personalized therapy for primary hepatocellular carcinoma (HCC).

Nanocarriers

10.1186/s12885-024-12006-1

Cite

Citations (5)

Causal role of 731 immune cells in pancreatic cancer: a Mendelian Randomization study

Journal of Pancreatology (2025)

Zhengyuan Feng Ruiqi Cao Jiaoxing Wu Jiantao Mo Qiqi Wang

Background: Pancreatic cancer poses a significant worldwide health challenge. Immune cells are implicated in pancreatic cancer progression and therapy, yet the precise influence of distinct subsets of immune cells remains largely unexplored. The objective of this study is to pinpoint immunophenotypes linked to pancreatic cancer. Methods: Two-sample Mendelian randomization (MR) analysis was employed. Immune phenotypes were retrieved from GWAS, and pancreatic cancer data from the IEU project was split into training and validation sets. Causality was evaluated using the IVW, MR Egger, and weighted median methods. Evaluation included MR-Egger intercept test, funnel plot, leave-one-out analysis for horizontal pleiotropy, and Cochran's Q test for heterogeneity. Estimates from the two sets were combined using the fixed-effects meta-analysis methods. Results: 6 immunophenotypes exhibiting inhibitory effects and 1 showing promoting role. Which is CD20 on IgD + CD38 - naive B cells (95% CI=0.765~0.948, P=0.003, OR = 0.852), CD24 on unsw mem B cells (95% CI=0.861~0.975, P=0.006, OR = 0.917), CD25 on B cells (95% CI=0.859~0.978, P=0.008, OR = 0.917), CD64 on monocyte (95% CI=0.802~0.921, P<0.001, OR = 0.859), CD25 on resting Treg cells (95% CI=0.784~0.957, P=0.005, OR = 0.866), CD39+ CD8br AC Treg cells (95% CI=0.816~0.971, P=0.008, OR = 0.890), HLA DR on B cell (95% CI=1.055~1.206, P<0.001, OR = 1.128) . None immunophenotype displayed potential reverse causality. The reliability of these results was confirmed by the fixed-effects meta-analysis methods. Conclusion: Our study has unveiled causal relationships between immunophenotypes and pancreatic cancer, which can offer guidance for future clinical and basic research endeavors.

Mendelian Randomization

10.1097/jp9.0000000000000212

Cite

Citations (0)

Huaier enhances the tumor-killing effect and reverses gemcitabine-induced stemness by suppressing FoxM1

Phytomedicine (2024)

Qiqi Wang Mengyuan Gong Ru‐Juan Liu Jiantao Mo Ruiping Bai

Gemcitabine is the first-line chemotherapy drug that can easily cause chemotherapy resistance. Huaier is a traditional Chinese medicine and shows an antitumor effect in pancreatic cancer, but whether it can enhance the gemcitabine chemotherapeutic response and the potential mechanism remain unknown.

FOXM1

10.1016/j.phymed.2024.155656

Cite

Citations (1)

Exosomal lncRNA TUG1 from cancer-associated fibroblasts promotes liver cancer cell migration, invasion, and glycolysis by regulating the miR-524-5p/SIX1 axis

Cellular & Molecular Biology Letters (2022)

Le Lü Jingjing Huang Jiantao Mo Xuanbo Da Qiao‐Xin Li

Increasing evidence suggests that taurine upregulated gene 1 (TUG1) is crucial for tumor progression; however, its role in hepatocellular carcinoma (HCC) and the underlying mechanisms are not well characterized.The expression levels of TUG1, miR-524-5p, and sine oculis homeobox homolog 1 (SIX1) were determined using quantitative real-time PCR. The regulatory relationships were confirmed by dual-luciferase reporter assay. Cell proliferation and invasion were assessed using Cell Counting Kit 8 and transwell assays. Glucose uptake, cellular levels of lactate, lactate dehydrogenase (LDH), and adenosine triphosphate (ATP) were detected using commercially available kits. Silencing of TUG1 or SIX1 was performed by lentivirus transduction. Protein levels were measured by immunoblotting.Cancer-associated fibroblasts (CAFs)-secreted exosomes promoted migration, invasion, and glycolysis in HepG2 cells by releasing TUG1. The promotive effects of CAFs-secreted exosomes were attenuated by silencing of TUG1. TUG1 and SIX1 are targets of miR-524-5p. SIX1 knockdown inhibited the promotive effects of miR-524-5p inhibitor. Silencing of TUG1 suppressed tumor growth and lung metastasis and therefore increased survival of xenograft model mice. We also found that TUG1 and SIX1 were increased in HCC patients with metastasis while miR-524-5p was decreased in HCC patients with metastasis.CAFs-derived exosomal TUG1 promoted migration, invasion, and glycolysis in HCC cells via the miR-524-5p/SIX1 axis. These findings may help establish the foundation for the development of therapeutics strategies and clinical management for HCC in future.

Lactate dehydrogenase A

10.1186/s11658-022-00309-9

Cite

Citations (90)

Targeted co-delivery of PD-L1 monoclonal antibody and sorafenib to circulating tumor cells via platelet-functionalized nanocarriers

Biochemical and Biophysical Research Communications (2023)

Xuanbo Da Jiantao Mo Qiao‐Xin Li Bangping Cao Jingjing Huang

Nanocarriers

Biodistribution

Circulating tumor cell

10.1016/j.bbrc.2023.05.124

Cite